Moderna submitted an emergency use authorization request Sept. 23 for its bivalent, omicron-targeted boosters for 12- to 17-year-olds and 6- to 11-year-olds, the company tweeted. Pfizer followed three days later with its application for 5- to 11-year-olds.
Currently, Moderna’s updated booster shot is authorized for adults 18 and older, and Pfizer’s option is authorized for ages 12 and up. As of Sept. 21, 4.4 million people — or about 1.5 percent of the U.S. population that’s eligible for the new booster — have received the updated booster.
In another tweet, Moderna said it plans to seek authorization for its omicron booster for children as young as 6 months old by the end of 2022. Pfizer did not give a projected date for its tweaked booster for the youngest population, but the drugmaker has a phase 1/2/3 clinical study underway testing it.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.